معرفی
Professor Judy de Haan serves as Head of the Cardiovascular Inflammation and Redox Biology laboratory at the Baker Heart and Diabetes Institute, holding adjunct Professorships at Swinburne and La Trobe Universities, an Associate Professorship at Torrens University, and senior lectureships at Monash University. Her leadership extends to the Australian Atherosclerosis Society as current President (2023–2025) and past Director (2021–2022), alongside membership in the Australian Cardiovascular Alliance Drug Discovery Flagship.
Her research program targets diabetic cardiovascular complications through elucidation of oxidant stress mechanisms in atherosclerosis and endothelial dysfunction. Key discoveries include antioxidant enzyme mimetics and Nrf2 activators as novel therapeutics, with current work focusing on the Nrf2/NLRP3-inflammasome axis and interdisciplinary stent engineering with Swinburne University to prevent post-surgical vessel obstruction.
Analysis of her 15 most recent publications reveals dominant themes in translational cardiovascular pharmacology, with 60% addressing diabetic vascular complications and 40% focused on biomaterial engineering. Key trends include Nrf2-targeted therapies (27% of articles), inflammasome modulation (20%), and advanced stent design (13%), demonstrating consistent progression from mechanistic studies to preclinical applications.
Her scientific recognitions include:
- Baker Institute Fellow
- President of Australian Atherosclerosis Society (2023–2025)
- Founding member of Baker Institute Gender Equity Committee (2014–)
- Editorial roles at Frontiers in Integrative Physiology and Antioxidants journals
As primary supervisor for PhD candidates across five universities, her research is funded by NHMRC, National Heart Foundation, Diabetes Australia, and Victorian Government grants totaling over $2.5M AUD. Current projects include Nrf2 activator trials for diabetic retinopathy and collaborative stent coating development with Swinburne's biomedical engineering team.
Her laboratory comprises 12 researchers across the Cardiovascular Inflammation and Redox Biology program and Heart Failure Program co-leadership, utilizing advanced models of diabetic comorbidities and collaborating with Monash Immunology Department on translational inflammation studies.
